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Background: The diagnosis of myocarditis is challenging due to its varying clinical presentation. Since myocarditis
can be associated with significant 5-year mortality, and postmortem data show myocarditis in almost 10% of all
adults suffering sudden cardiac death, individual risk stratification for patients with suspected myocarditis is of great
clinical interest. We sought to demonstrate that patients with clinically suspected myocarditis and a normal
cardiovascular magnetic resonance (CMR) according to our definition have a good prognosis, independent of their
clinical symptoms and other findings.
Methods: Prospective clinical long-term follow-up of consecutive patients undergoing CMR for work-up of clinically
suspected myocarditis at our institution in 2007-2008.
Results: Follow-up was available for n = 405 patients (all-comers, 54.8% inpatients, 38% outpatient referrals from
cardiologists). Median follow-up time was 1591 days. CMR diagnosis was “myocarditis” in 28.8%, “normal” in 55.6% and
“other pathology” in 15.6%. Normal CMR was defined as normal left ventricular (LV) volumes and normal left ventricular
ejection fraction (LV-EF) in the absence of late Gadolinium Enhancement (LGE). The overall mortality was 3.2%. There
were seven cardiac deaths during follow-up, in addition one aborted SCD and two patients had appropriate internal
cardioverter defibrillator (ICD) shocks – all of these occurred in patients with abnormal CMR. Kaplan-Meier analysis with
log-rank test showed significant difference for major adverse cardiac events (cardiac death, sudden cardiac death (SCD),
ICD discharge, aborted SCD) between patients with normal and abnormal CMR (p = 0.0003).
Conclusion: In our unselected population of consecutive patients referred for CMR work-up of clinically suspected
myocarditis, patients with normal CMR have a good prognosis independent of their clinical symptoms and other
findings.
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The diagnosis of myocarditis is challenging due to its
varying clinical presentation. Especially in patients with
non-specific or mild symptoms it can be difficult to
make or to exclude. This is a major clinical problem,
since patients with severe forms of myocarditis were re-
cently shown to have a 5-year mortality of almost 20% [1].
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stated.10% of all adults suffering sudden cardiac death (SCD) [2].
Therefore, individual risk stratification for patients with
suspected myocarditis is of great clinical interest.
Cardiovascular magnetic resonance (CMR) offers im-
portant incremental prognostic information in a variety
of cardiac diseases like different forms of cardiomyopa-
thies or coronary artery disease [3-5], and also shows
promise for risk stratification in inflammatory myocar-
dial disease [1,6].
Consequently, we hypothesized that patients referred
for CMR work-up of suspected myocarditis can be risk
stratified on the basis of routine CMR parameters, suchal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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of late gadolinium enhancement (LGE). In particular, we
sought to demonstrate that patients with clinically sus-
pected myocarditis that have a normal CMR according
to our definition have a good prognosis, independent of
their clinical symptoms and other findings.Methods
Patient population
We prospectively followed 405 consecutive patients who
underwent CMR for work-up of clinically suspected
myocarditis at our institution between 01.01.2007 and
03.07.2008. Thus, the main inclusion criteria was a clin-
ical suspicion for myocarditis by each treating physician
that was strong enough to refer the patient for CMR
work-up of suspected myocarditis, reflecting a real world
clinical routine population. Patients with previously
known coronary artery disease (CAD), post myocardial
infarction, or relevant valvular diseases, as well as
patients with previously known malignancies, other ter-
minal illness, or non-diagnostic images were excluded
(Figure 1). The local ethics committee (University of
Tübingen, Germany) approved data collection and man-
agement and each patient gave informed consent. Some of
the patients (n = 25) were part of a previous report [1].
In the current cohort, endomyocardial biopsy (EMB)
was not routine part of the study protocol as in previous
cohorts [1,7], but was only performed if clinically indi-
cated [8]. Histopathological analysis and immunohistol-
ogy were used to evaluate EMB samples as described
previously [1,7,9].CMR protocol and analysis
Electrocardiogram (ECG) gated CMR imaging was per-
formed in breath-hold using a 1.5 T Magnetom SonataFigure 1 Flow chart visualizing the derivation of the study population.(Siemens-Healthcare, Germany) in line with recommen-
dations of the Society of CMR (SCMR) and the European
Society of Cardiology (ESC) Working Group EuroCMR,
respectively [10]. Both cine and LGE short axis CMR
images were prescribed every 10 mm (slice thickness
6 mm) from base to apex. In-plane resolution was typic-
ally 1.2×1.8 mm. Cine CMR was performed using a
steady-state-free-precession-sequence. LGE images were
acquired on average 5–10 minutes after contrast adminis-
tration using segmented inversion recovery gradient echo
sequences (IR-GRE) [11] constantly adjusting inversion
time to null normal myocardium [12]. The contrast
dose (gadodiamide or gadopentetate-dimeglumine) was
0.15 mmol/kg.
Cine and contrast images were evaluated by two expe-
rienced observers as described elsewhere [7]. In brief;
endocardial and epicardial borders were outlined on the
short-axis cine images, papillary muscles were treated as
myocardium and included in the analysis. Volumes and
ejection-fraction were derived by summation of epicar-
dial and endocardial contours. The extent of LGE was
assessed using the Siemens Argus analysis software
package. The extent of LGE was assessed on the short-
axis contrast images with the use of an image intensity
level ± 2 SD above the mean of remote myocardium to
define LGE [1,7,9].
Clinical follow-up, variables, endpoints and definitions
All variables were collected directly from patients, and/
or medical records except CMR parameters, which were
evaluated as described above. Most variables are self-
explanatory; all others are defined below.
Clinical follow-up was performed using a standardized
telephone questionnaire at the earliest three years after
initial presentation for CMR. In case of a suspected
event, all necessary medical records were obtained and
reviewed in blinded fashion by some of the authors (J.S.,
S.G., H.M.) acting as an end point committee.
The predefined primary endpoints were major adverse
cardiac events, including cardiac death, sudden cardiac
death, aborted sudden cardiac death, and appropriate ICD
discharge. The secondary endpoint was defined as a
composite of primary endpoint and hospitalization for
heart failure. In detail, the following definitions were used:
Major adverse cardiac event: All cardiac death,
including SCD, and aborted SCD.
Cardiac death: death from all cardiac causes.
SCD: unexpected arrest of presumed cardiac origin
within one hour after onset of any symptoms that
could be interpreted as being cardiac in origin.
Aborted sudden cardiac death was defined as
resuscitation after cardiac arrest in a patient who
remained alive 28 days later.
Table 1 Baseline patient characteristics
All patients with follow-up 405 (92.5)
Time to follow-up [days] 1591 (1490–1739)
Gender, female 177 (43.7)
Age [years] 47.9 (36.9-60.8)
Referring physician
Inpatients 222 (54.8)
Outpatients referred by cardiologists 154 (38.0)
Outpatients referred by general practitioners 29 (7.2)
Primary cardiac symptoms leading to CMR
(multiple possible)
Reduced LVEF 82 (20.2)
Pericardial effusion 6 (1.5)
ECG abnormality 131 (32.3)
Palpitations 92 (22.7)
Dyspnea 137 (33.8)
Angina/Chest pain 217 (53.6)
Abnormal fatigue 96 (23.8)
Wall motion abnormality 17 (4.2)
Ventricular arrythmias/Extrasystoles 45 (11.1)
Aborted SCD 6 (1.5)
Viral prodrome/history of infectious symptoms 130 (32.1)
Atrial fibrillation 50 (12.4)
Elevated troponin 38 (9.4)
Coronary angiography performed 205 (50.6)
EMB performed 78 (20.5)
Histopathological myocarditis in EMB 53 (68.8)
PVB19 29 (37.7)
HHV6 12 (15.6)
Double infection PVB19/HHV6 10 (13.0)
EBV 1 (1.3)
CMR imaging parameters
LVEF [%] 62.5 (55.0-68.0)
LV-EDV [ml] 137 (110–164)
LV-ESV [ml] 50 (36–72)
LVEDD [mm] 50 (46.0-54.5)
Pericardial effusion present 76 (18.8)
LGE present 114 (28.3)
Final diagnosis based on CMR
No cardiac pathology 225 (55.6)
Myocarditis 116 (28.8)
Other cardiac pathology 63 (15.6)
Values shown are n (%) or medians and IQR = interquartile range (25th-75th
percentiles) CMR, cardiovascular magnetic resonance; LVEF, left ventricular
ejection fraction; SCD, sudden cardiac death, EMB, endomyocardial biopsy,
PVB19, parvovirus B 19; HHV6, human herpes virus 6; EBV, ebstein-barr virus;
CMR, cardiovascular magnetic resonance; EDV, enddiastolic volume; ESV,
endsystolic volume; LVEDD, left ventricular enddiastolic diameter; LGE, late
gadolinium enhancement.
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included automatic defibrillation shocks triggered by
ventricular tachycardia or fibrillation and documented
by stored intracardiac electrocardiographic or cycle-
length data.
Hospitalization for heart failure: Hospitalization as an
in-patient >24 h, and heart failure as primary diagnosis
according to the hospitals final report.
A normal CMR was defined as left ventricular ejection
fraction (LV-EF) ≥ 60%, AND left ventricular end-
diastolic volume (LV-EDV) ≤ 180 ml, AND no LGE
present.
Statistical analysis
Absolute numbers, percentages and medians (with quar-
tiles) were computed to describe the patient population.
Categorical variables were compared by chi-square test
or Fisher exact test as appropriate; continuous parame-
ters by using Wilcoxon rank-sum test. Kaplan Meier
curves were calculated for visualizing the cumulative
event-free survival of patients with normal and abnormal
CMR for both endpoints. A log-rank test was performed
to compare both survival curves. A multivariable Cox
proportional hazard model was used for analyzing inde-
pendent associations with cardiac mortality and the
secondary endpoint. P-values <0.05 were considered sig-
nificant. All p-values are results of two-tailed tests. Stat-
istical analyses were performed using the SAS© statistical
package, version 9.2 (SAS, Cary, North Carolina).
Results
Patient characteristics
Baseline characteristics are displayed in Table 1. Follow-
up was available for n = 405 patients (all-comers, 54.8%
in-patients, 38% referrals from cardiologists) (Figure 1).
Median follow-up time was 1591 days. Most frequent
symptoms or findings leading to CMR were angina/chest
pain (53.6%), dyspnea (33.8%) and ECG abnormalities
(32.3%) (several symptoms or findings could be present,
thus these numbers do not add up to 100%). Viral pro-
dromes, such as gastrointestinal or upper respiratory
symptoms, were present in 32.1% of patients. Invasive
coronary angiography was performed in 50.6% of the
patients because CAD was suspected initially, including
all patients older than 50 years and some younger
patients with extensive cardiovascular risk profiles or
ECG abnormalities suggesting coronary artery disease.
CAD was detected in two of the included patients
(0.5%), but both had no stenosis >50% of any large
epicardial vessel (maximum was distal 70% RPLD-
stenosis), and CAD was deemed not responsible for their
clinical complaints (both heart failure).
The CMR diagnosis “myocarditis” was made in 28.8%,
“normal” in 55.6%, and “other cardiac pathology (e.g.
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demonstrate that patients with clinically suspected myo-
carditis and normal CMR have a good prognosis, the
cohort was divided in those with normal CMR (55.6%),
and those with abnormal CMR (44.4%, comprising CMR
diagnosis of myocarditis, as well as other cardiac path-
ology). Clinically indicated EMB was performed in 20.5%
of the patients, revealing myocarditis in 68.8% of cases,
with PVB 19 as the most common virus.
All patients presenting with heart failure were started
with heart failure treatment according to the guidelines
applicable at that time [13], which was continued at the
discretion of the individual patient’s cardiologist. If indi-
cated, an ICD was offered, which was accepted by 14
patients. Twelve of these had an abnormal CMR, and 2
patients a normal CMR (one of those got an ICD for
secondary prophylaxis following survived SCD as index
event leading to CMR work-up, the other because an ion
channel disease was diagnosed during follow-up).
CMR findings
The median time between onset of symptoms and the
CMR scan was 14 days, ranging from 1–70 days. Mean
LV-EF of all patients was 62.5%, mean LV-EDV was
137 ml. LGE was present in 28.3% of the patients, peri-
cardial effusion in 18.8%. A normal CMR (defined as
LV-EF ≥ 60%, AND LV-EDV ≤ 180 ml, AND no LGE
present) was found in 55.6% of patients.
Dividing the patients in two groups (normal CMR vs.
abnormal CMR) revealed several differences at baseline
(Table 2): Patients with normal CMR were more often
female (54.2% vs. 30.6%), and palpitations as the primary
symptom leading to CMR was more frequent. Dyspnea
as primary symptom was more frequent in patients with
abnormal CMR (43.3 vs. 26.2%, p < 0.001), while chest
pain was more often reported in patients with normal
CMR (47.2 vs. 58.7%, p < 0.05). Figure 2 displays CMR
results of two patients who presented with similar symp-
toms (i.e. dyspnea and chest pain) but had totally differ-
ent findings in CMR and different clinical outcomes.
There was no difference in the frequency of viral pro-
dromes in the two groups (30.7 vs. 33.9%, p = 0.49). An
elevated troponin was more likely in patients with ab-
normal CMR (16.7 vs. 3.6%, p < 0.0001), but not very fre-
quent overall. Clinically indicated EMB was performed
in 38.6% of the patients with abnormal CMR, and 5.7%
of those with normal CMR. In the patients with normal
CMR the clinical suspicion of myocarditis was that
strong that EMB was done to verify the diagnosis in the
absence of CMR findings. Myocarditis was diagnosed in
the majority of all patients who underwent EMB (58.3%
of those with normal CMR, and 70.8% of those with
abnormal CMR). Parvovirus B19 was the most common
virus, followed by human herpes virus 6. Note thatindependently of histopathological findings no patient
with normal CMR suffered cardiac death or any major
event, which is illustrated by Figure 3.
Follow-up results
During follow-up 13 patients died, (11 of these with
abnormal CMR and two patients with normal CMR),
yielding an overall mortality of 3.2%. One of the two
patients with normal CMR who died was 91 years old
and died of major stroke, the other died at 61 years from
bronchial carcinoma that had been accidentally diag-
nosed at index CMR. In the abnormal CMR group there
were 10 major adverse cardiac events, including seven
cardiac deaths, one aborted SCD and two cases of
appropriate ICD shocks. In addition, four patients died
from non-cardiac reasons (one car accident and three
malignancies). Tables 3 and 4 demonstrate univariate
analyses for the primary and secondary endpoints. We
found no significant correlation between events and
clinical symptoms leading to CMR, except for reduced
ejection fraction (both endpoints) and dyspnea, which
were significantly more frequent in patients with cardiac
death or hospitalization for heart failure. Figure 4
displays CMR images of three patients who all presented
with symptoms and histories typical for myocarditis, but
had normal results on CMR; none of these patients
suffered an event.
Heart failure medication at follow-up was more com-
mon in patients with abnormal CMR (β-blocker in
49.1% vs. 24.4%, p < 0.0001, ACEI/ARB in 41.7% vs.
18.7%, <0.0001), and both β-blockers and ACE/ARB were
taken frequently by patients suffering events (87% β-
blocker and ACE/ARB in patients reaching endpoint 2).
All CMR parameters evaluated were significantly dif-
ferent between patients who had an event and those
who did not. The odds ratio (OR) for the presence of
LGE for the primary endpoint in univariate analyses was
10.83 (2.26-51.82), p <0.001.
Kaplan-Meier analysis with log-rank test shows a signifi-
cant difference for the primary endpoint (cardiac death,
appropriate ICD discharge and aborted sudden cardiac
death) between patients with normal and abnormal CMR
(p = 0.0003), as well as for the secondary endpoint (end-
point 1 + hospitalization for heart failure, p < 0.0001).
Kaplan-Meier curves can be viewed in Figure 5.
Multivariate Cox proportional hazards regression ana-
lysis including the presence of LGE, LV-EF and LV-EDV
as measured by CMR revealed LV-EF as the best inde-
pendent predictor of cardiac mortality (primary end-
point, hazard ratio [HR]: 0.939 per % increase, p = 0.01).
In this model neither initial LV-EDV (HR: 0.999 per ml
increase, p = 0.87) nor presence of LGE (HR: 3.98,
p = 0.11) reached significance. Looking at endpoint 2,
both LGE (HR: 2.919, p = 0.02), and LV-EF (HR: 0.965
Table 2 Characteristics of patients with normal (no Pathology) and abnormal (any Pathology) CMR
CMR normal CMR not normal p-value OR (95% - CI)
(n = 225) (n = 180)
Age [years] 46 (35.6-57.1) 49.7 (38.6-64.3) <0.01
Gender, female 122 (54.2) 55 (30.6) <0.0001 2.69 (1.78-4.06)
Referring physician
Inpatients 108 (48.0) 114 (63.3) <0.01 0.56 (0.38-0.84)
Outpatients referred by cardiologists 98 (43.6) 56 (31.1) <0.05 1.71 (1.13-2.58)
Outpatients referred by general practitioners 19 (8.4) 10 (5.6) 0.26 1.57 (0.71-3.46)
Primary cardiac symptoms leading to CMR
Reduced LVEF 15 (6.7) 67 (37.2) <0.0001 0.12 (0.07-0.22)
Pericardial effusion 4 (1.8) 2 (1.1) 0.58 1.61 (0.29-8.90)
ECG abnormality 77 (34.2) 54 (30.0) 0.37 1.21 (0.80-1.85)
Palpitations 66 (29.3) 26 (14.4) <0.001 2.46 (1.48-4.07)
Dyspnea 59 (26.2) 78 (43.3) <0.001 0.46 (0.31-0.71)
Angina/Chest pain 132 (58.7) 85 (47.2) <0.05 1.59 (1.07-2.35)
Abnormal fatigue 57 (25.3) 39 (21.8) 0.41 1.22 (0.77-1.94)
Wall motion abnormality 8 (3.6) 9 (5.0) 0.47 0.70 (0.26-1.85)
Ventricular arrythmias/Extrasystoles 29 (12.9) 16 (8.9) 0.20 1.52 (0.80-2.89)
Aborted SCD 3 (1.3) 3 (1.7) 0.78 0.80 (0.16-4.00)
Viral prodrome/history of infectious symptoms 69 (30.7) 61 (33.9) 0.49 0.86 (0.57-1.31)
Atrial fibrillation 14 (6.2) 36 (20.1) <0.0001 0.26 (0.14-0.51)
Elevated troponin 8(3.6) 30 (16.7) <0.0001 0.18 (0.08-0.41)
EMB performed 12 (5.7) 66 (38.6) <0.0001 0.10 (0.05-0.19)
Histopathological myocarditis in EMB 7 (58.3) 46 (70.8) 0.39 0.58 (0.16-2.05)
CMR imaging parameters
LVEF [%] 66 (62.0-70.0) 54 (38.0-63.0) <0.0001
LV-EDV [ml] 122 (103–148) 160 (128–204) <0.0001
LV-ESV [ml] 42 (32.0-51.5) 72 (52–109) <0.0001
LVEDD [mm] 48 (44–52) 54 (49–59) <0.0001
Pericardial effusion present 0 76 (42.5) <0.0001
LGE present 0 114 (64.0) <0.0001
Symptoms at follow-up
Angina pectoris 40 (19.8) 23 (15.0) 0.24 1.40 (0.80-2.45)
Other chest pain (non anginal) 17 (8.5) 15 (9.8) 0.66 0.85 (0.41-1.76)
Palpitations 34 (16.9) 22 (14.4) 0.52 1.21 (0.68-2.17)
NYHA class ≥ 2 53 (24.9) 58 (36.3) <0.05 0.58 (0.37-0.91)
Medication
Betablockers at follow-up 51 (24.4) 80 (49.1) <0.0001 0.33 (0.22-0.52)
ACEI/ARB at follow-up 39 (18.7) 68 (41.7) <0.0001 0.32 (0.20-0.51)
Events during follow-up
Death 2 (0.9) 11 (6.1) <0.01 0.14 (0.03-0.63)
Cardiac death 0 7 (63.6) 0.51
Aborted SCD 0 1 (0.6) 0.25
ICD shocks 0 2 (1.3) 0.10
Hospitalization for heart failure 1 (0.5) 16 (9.5) <0.0001 0.04 (0.01-0.34)
Values shown are n (%) or medians (25th–75th percentile). Abbreviations are the same as in Table 1.






Figure 2 Patients with similar symptoms, but different CMR results and outcomes. Patient 250 presented with dyspnea and chest pain,
the same symptoms as patient 161. While in patient 250 CMR revealed an EF of 22% and epicardial LGE of the posterolateral wall typical for
myocarditis (EMB: viral HHV6 myocarditis, no other pathology (e.g. no sarcoid)), patient 161 had a normal CMR. Patient 250 died from SCD
during follow-up while patient 161 had no events.
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while LV-EDV (HR per ml increase 1.002, p = 0.33) did
not reach significance.
Discussion
This is the largest long-term follow-up dataset evaluat-
ing the prognostic value of clinical routine CMR in
patients with clinically suspected myocarditis (n = 405).
We found that a significant number of patients with
abnormal CMR suffered major adverse cardiac events
(cardiac death, ICD discharge, or aborted SCD, n = 10,
5.6% of all patients with abnormal CMR), while no
patient with normal CMR had any major adverse cardiac
event. Interestingly, only one patient with normal CMR
suffered any cardiac event (one hospitalization for heart-Patient 3
Diastole Systole
Patient 55
Figure 3 Patients with histologically proven myocarditis, but differen
myocarditis with low copy numbers of PVB19. CMR revealed impaired vent
and septal LGE. The patient suffered SCD during follow-up. Patient 55 suff
an elevated troponin. EMB revealed chronic myocarditis with intramyocard
patient did not suffer any events and did not report any cardiac symptomsfailure only). Kaplan-Meier analysis with log-rank test
confirmed a highly significant prognostic difference be-
tween patients with normal and abnormal CMR regard-
ing major adverse and all adverse events.Patient characteristics
Most patients presented or were referred for work-up of
chest pain, dyspnea, or ECG abnormalities, reflecting a
much less symptomatic population in comparison to our
previous reports [1,7,9]. This is also underscored by the
fact that in the current population just 9.4% of patients
had elevated troponin at presentation. However, types of
viruses found are similar to our [1,7,9] and other previ-
ous reports [14,15].LGE
t CMR results and outcomes. Patient 3 EMB demonstrated
ricular function (LV-EF 36%) in an enlarged left ventricle (EDV 190 ml)
ered from chest pain and abnormal fatigue, blood chemistry returned
ial presence of HHV6 and PVB19, but CMR was completely normal. This
at follow-up.
Table 3 Endpoint 1 – cardiac death, aborted SCD, appropriate ICD discharge
Endpoint 1 No endpoint p-value OR (95% - CI)
(n = 10) (n = 395)
Age [years] 66.1 (59.2-68.6) 47.7 (36.4-60.2) <0.01
Gender, female 4 (40) 173 (43.8) 0.81 0.86 (0.24-3.08)
Referring physician
Inpatients 7(70) 215 (54.4) 0.31 1.99 (0.51-7.82)
Outpatients referred by cardiologists 3 (30) 151 (38.2) 0.60 0.69 (0.18-2.72)
Outpatients referred by general practitioners 0 29 (7.3) 0.37
Primary cardiac symptoms leading to CMR
Reduced LVEF 6 (60) 76 (19.2) <0.01 6.30 (1.73-22.86)
Pericardial effusion 0 (0) 6 (1.5) 0.69
ECG abnormality 3 (30) 128 (32.4) 0.87 0.89 (0.23-3.51)
Palpitations 1 (10) 91 (23) 0.33 0.37 (0.05-2.97)
Dyspnea 6 (60) 131 (33.2) 0.08 3.02 (0.84-10.90)
Angina/Chest pain 4 (40) 213 (53.9) 0.38 0.57 (0.16-2.05)
Abnormal fatigue 2 (20) 94 (23.9) 0.78 0.80 (0.17-3.82)
Wall motion abnormality 0 17 (4.3) 0.50
Ventricular arrythmias/Extrasystoles 0 45 (11.4) 0.26
Aborted SCD 0 6 (1.5) 0.69
Viral prodrome/history of infectious symptoms 2 (20) 128 (32.4) 0.41 0.52 (0.11-2.49)
Atrial fibrillation 2 (20) 48 (12.2) 0.46 1.80 (0.37-8.74)
Elevated troponin 0 38 (9.6) 0.30
EMB performed 6 (60) 72 (19.5) <0.01 6.21 (1.71-22.58)
Histopathological myocarditis in EMB 4 (66.7) 49 (69) 0.91 0.90 (0.15-5.27)
CMR imaging parameters
LVEF [%] 34.5 (22.0-43.0) 63.0 (56–69) <0.0001
LV-EDV [ml] 197 (144–269) 136 (110–163) <0.01
LV-ESV [ml] 127 (86–188) 49 (36–68) <0.001
LVEDD [mm] 61 (54–65) 50 (46–54) <0.01
Pericardial effusion present 6 (60) 70 (17.7) <0.01 6.94 (1.91-25.25)
LGE present 8 (80.0) 106 (27) <0.001 10.83 (2.26-51.82)
Final diagnosis based on CMR
No cardiac pathology 0 225 (57) <0.001
Myocarditis 8 (80) 108 (27.3) <0.001 10.63 (2.22-50.85)
Other cardiac pathology 2 (20) 61 (15.4) 0.69 1.37 (0.28-6.60)
Medication
Betablockers at follow-up 6 (75) 125 (34.3) <0.05 5.74 (1.14-28.84)
ACEI/ARB at follow-up 7 (87.5) 100 (27.5) <0.001 18.48 (2.25-152.1)
Values shown are n (%) or medians (25th -75th percentiles) Abbreviations are the same as in Table 1.
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We found a broad range of normal or enlarged ventri-
cles with either normal or impaired function. Two-
hundred-twenty-five patients had a completely normal
CMR according to our definition, whereas 180 patients
had an abnormal CMR. LGE was present in 118 of the
180 abnormal patients, yielding a prevalence of 28.3% inthe entire population, and was usually located in the
subepicardial or intramural areas of the LV, which is in
line with previous findings [7,9,16].
Interestingly, patients presenting with dyspnea as pri-
mary symptom had an abnormal CMR more frequently
(43.3 vs. 26.2%, p < 0.001), while chest pain was more
often reported by patients with normal CMR (47.2 vs.
Table 4 Endpoint 2 – death, aborted SCD, appropriate ICD discharge or hospitalization for heart failure
Endpoint 2 No endpoint p-value OR (95% - CI)
(n = 26) (n = 379)
Age [years] 61.1 (51.2-68.6) 47 (36–59.5) <0.001
Gender, female 9 (34.6) 168 (44.3) 0.33 0.66 (0.29-1.53)
Referring physician
Inpatients 21 (80.8) 201 (53.0) <0.01 3.80 (1.40-10.28)
Outpatients referred by cardiologists 5 (19.2) 149 (39.3) <0.05 0.37 (0.14-0.99)
Outpatients referred by general practitioners 0 29 (7.7) 0.14
Primary cardiac symptoms leading to CMR
Reduced LVEF 15 (57.7) 67 (17.7) <0.0001 6.35 (2.79-14.44)
Pericardial effusion 0 6 (1.6) 0.52
ECG abnormality 7 (26.9) 124 (32.7) 0.54 0.76 (0.31-1.85)
Palpitations 5 (19.2) 87 (23) 0.66 0.80 (0.29-2.18)
Dyspnea 18 (69.2) 119 (31.4) <0.0001 4.92 (2.08-11.62)
Angina/Chest pain 10 (38.5) 207 (54.6) 0.11 0.52 (0.23-1.17)
Abnormal fatigue 4 (15.4) 92 (24.3) 0.30 0.57 (0.19-1.68)
Wall motion abnormality 0 17 (4.5) 0.27
Ventricular arrythmias/Extrasystoles 2 (7.7) 43 (11.3) 0.57 0.65 (0.15-2.85)
Aborted SCD 0 6 (1.6) 0.52
Viral Prodrome/history of infectious symptoms 4 (15.4) 126 (33.2) 0.06 0.37 (0.05-2.81)
Atrial fibrillation 9 (34.6) 41 (10.8) <0.001 4.35 (1.82-10.39)
Elevated troponin 1 (3.8) 37 (9.8) 0.32 0.37 (0.05-2.81)
EMB performed 16 (64) 62 (17.5) <0.0001 8.40 (3.55-19.88)
Histological myocarditis in EMB 10 (62.5) 43 (70.5) 0.54 0.70 (0.22-2.21)
CMR imaging parameters
LVEF [%] 39 (22.0-59.0) 63 (57.0-69.0) <0.0001
LV-EDV [ml] 181 (126.0-284.0) 136 (108.0-162.0) <0.001
LV-ESV [ml] 123 (52.0-188.0) 49 (36.0-67.0) <0.0001
LVEDD [mm] 58.5 (54.0-65.0) 50 (45.0-54.0) <0.0001
Pericardial effusion present 11 (42.3) 65 (17.2) <0.01 3.53 (1.55-8.04)
LGE present 18 (69.2) 96 (25.5) <0.0001 6.59 (2.77-15.63)
Final diagnosis based on CMR
No cardiac pathology 1 (3.8) 224 (59.1) <0.0001 6.59 (2.77-15.63)
Myocarditis 17 (65.4) 99 (26.1) <0.0001 5.34 (2.31-12.37)
Other cardiac pathology 8 (30.8) 55 (14.5) <0.05 2.62 (1.09-6.32)
Medication
Betablockers at follow-up 20 (87.0) 111 (31.8) <0.0001 14.29 (4.16-49.11)
ACEI/ARB at follow-up 20 (87.0) 87 (24.09) <0.0001 20.08 (5.82-69.20)
Values shown are n (%) or medians (25th -75th percentiles) Abbreviations are the same as in Table 1.
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tion between symptoms, CMR findings and clinical out-
come [9].
As described by Grün et al. [1] and others [17] our
data also suggest that patients with scar demonstrated
by LGE have larger ventricles and poorer LV-EF com-
pared to those without scar (Table 2, abnormal CMR).As scarring may lead to LV dilatation and impaired LV-
EF, this finding conceptually makes sense.
Follow-up results
In our population of 405 consecutive patients presenting
for CMR work-up of clinically suspected myocarditis over-





Figure 4 CMR images of patients with different symptoms and histories suggestive of myocarditis. Patient 285: 48-year-old female
referred by a cardiologist for work-up of dyspnea, chest pain and abnormal fatigue, occurring after a viral infection. Patient 388: 28-year-old male
who presented with palpitations, chest pain and abnormal fatigue after sinusitis. ECG showed ST-elevations suggestive of myocarditis. Patient 248:
49-year-old male, suffering from dyspnea, palpitations and ventricular extrasystoles following viral gastroenteritis. All these patients had
normal CMR results, and in follow-up, there were no cardiac events in any of these patients. At follow-up, all were without any cardiac symptoms.
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biopsy proven myocarditis (3.2% vs. 19.2%), also under-
scoring the differences in morbidity between the all
comers presenting with mild symptoms in the present
population, and patients with biopsy proven myocarditis
previously reported.
In the group of 13 patients suffering death during
follow-up, only two individuals with normal CMR died.
As described above, those patients died from non-
cardiac events (stroke and malignancy, see Results),
whereas all other deaths occurred in the group of
patients with abnormal CMR, and the majority was
caused by cardiac events. Importantly, no patient with
normal CMR suffered cardiac death, or any other major
adverse cardiac event (Figure 5 upper panel). Only one
patient with normal CMR was hospitalized for heart fail-
ure during follow-up, emphasizing the prognostic impact
of a normal CMR in consecutive patients with clinically
suspected myocarditis.
Multivariate Cox analyses revealed LV-EF as the best
independent predictor of cardiac death in our group of
patients with suspected myocarditis, which is somewhat
discrepant to previous results [1,17]. This finding is most
likely explained by the low prevalence of LGE in the
current population (28.3% vs. 53.2% in the cohort
reported by Grün), and the lower rate of adverse events
(3.2% vs. 19.2%). Thus, it seems very likely, especially
with regard to the results of the univariate analysisdescribed above (OR for the presence of LGE for the pri-
mary endpoint 10.83, p < 0.001), that LGE (current
multivariate HR: 3.98, p = 0.11) would turn out to be sig-
nificant in a larger group with more events. This is also
supported by the fact that for endpoint 2 (including
hospitalization for heart failure) both presence of LGE
(HR: 2.919, p = 0.02), and LV-EF (HR: 0.965, p = 0.03)
were independent predictors of events.
Nevertheless, it is very important to keep in mind that
the main aim of this study was not to identify predictors
of adverse events in patients with suspected myocarditis,
but to establish clinical routine risk stratification of pa-
tients with suspected myocarditis by demonstrating that
adverse cardiac events are extremely rare in patients with
normal CMR, independent of their clinical symptoms.
Clinical implications
Although our data reveal a strong association between
a normal CMR and a good long-term prognosis for
consecutive patients presenting for CMR work-up of
clinically suspected myocarditis, prospectively designed
international trials and/or registries are required to
definitively establish CMR risk stratification in this
specific setting.
However, with regard to our current and previous
data [1] some recommendations for clinical manage-
ment seem appropriate: 1) The present data indicate
that patients with clinically suspected myocarditis and
Daysafter CMR
Patients at risk
CMR normal 223  220 217 182 17
CMR abnormal 175  172  162 140 15
Daysafter CMR
Patients at risk
CMR normal 223 219 216 181 17
CMR abnormal 174 169 152  131 15
A
B
Figure 5 Kaplan-Meier survival curves with regard to cardiac death, appropriate ICD discharge, aborted SCD (A), and cardiac death,
appropriate ICD discharge, aborted SCD and hospitalization for heart failure (B). The number of patients at risk is shown at the bottom of
the figures. Abbreviations as in Table 1.
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Although CMR certainly cannot always diagnose myo-
carditis (e.g. histopathological evidence of myocarditis
in some patients with normal CMR, who underwent
clinically indicated EMB, see Results), it seems to be
very effective in excluding relevant cardiac pathology
leading to adverse cardiac events. Thus, it represents a
powerful non-invasive tool for risk stratification in
patients with clinically suspected or known myocarditis,
which can give suffering patients and worrying physi-
cians some peace of mind independent of the clinical
symptoms and other findings. 2) As in previous data-
sets [1,9] we identified impaired LV-EF and symptoms
of heart failure as important predictors of adverse
cardiac events. This reproducible finding once more
suggests that one should carefully optimize heart failure
therapy in all patients with suspected or known myo-
carditis presenting with even the mildest physical signs
of heart failure.
However, as β-blockers were taken by most of the
patients suffering an adverse cardiac event, a protective
effect as suggested by other authors [14] cannot bederived from our current data, although such an effect
cannot be excluded.
Limitations
There may be a referral bias in the current population,
resulting in the inclusion of more healthy people. How-
ever, this seems not very likely since there was no
significant difference between the groups of inpatients,
referrals from cardiologists, and referrals from general
practitioners in reaching endpoint 1 vs. no endpoint
(see Table 3).
In addition, it might be criticized that EMB was per-
formed in only 20.5% of the current patients; while in
other important studies focusing on prognosis in myo-
carditis all patients underwent EMB [1,14,18,19]. How-
ever, according to current guidelines, EMB is not
commonly indicated [8]. Especially in patients without
any heart failure, or with late onset (> 4 weeks) the
risks of the procedure (including perforation, pericar-
dial tamponade, ventricular arrhythmias, embolization
and others) may outweigh the possible benefits. Based on
our study design (all comers with clinically suspected
Schumm et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:14 Page 11 of 12
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tion for EMB. Nevertheless, all had symptoms suggestive
of myocarditis leading to presentation at a cardiologist or
hospital admittance, and although CMR certainly cannot
always diagnose myocarditis [20] it seems to be very
effective in excluding relevant cardiac pathology leading
to adverse cardiac events.
Conclusions
In our unselected population of consecutive patients
referred for CMR work-up of clinically suspected myo-
carditis, patients with normal CMR (according to our
definition) have a good prognosis, independent of their
clinical symptoms and other findings.
Thus, CMR represents a powerful non-invasive tool to
identify patients with clinically suspected myocarditis
who are at low risk for future events and hence may
benefit from advice to getting back to normal life soon
after symptoms abate.
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